A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

AIDS

Volumn 16, Issue 4, 2002, Pages 579-588

  Cohen, Calvin J ^a   Hunt, Susan ^a   Sension, Michael ^a   Farthing, Charles ^a   Conant, Marcus ^a   Jacobson, Susan ^a   Nadler, Jeffrey ^a   Verbiest, Werner ^a   Hertogs, Kurt ^a   Ames, Michael ^a   Rinehart, Alex R ^a   Graham, Neil M ^a   Arduino, Roberto ^a   Brosgart, Carol ^a   Brown, Stephen ^a   Collier, Ann ^a   Davis, Steven ^a   Galpin, Jeffrey ^a   Goodgame, Jeffrey ^a   Grossman, Howard ^a   Henry, W Keith ^a   Kessler, Harold ^a   Markowitz, Martin ^a   Mayers, Douglas ^a   Saag, Michael ^a   Schrader, Shannon ^a   Stein, Allan ^a   Stryker, Richard ^a   Thompson, Melanie ^a   Torres, Gabriel ^a   Copeland, Deborah ^a   more..

^a Tibotec Virco USA   (United States)

Author keywords

Clinical trials; Highly active antiretroviral therapy; HIV diagnostic tests; HIV drug resistance resistance mutations; Phenotypic resistance testing

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORPHOLOGICAL TRAIT; OUTCOMES RESEARCH; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VIRUS LOAD; VIRUS MUTATION;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 0037040360     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203080-00009     Document Type: Article

References (25)

1. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
2. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
3. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
4. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
5. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated subjects
6. Viral dynamics in HIV-1 infection
7. Antiretroviral drug resistance testing in adult HIV-1 infection
8. Introduction of HIV drug-resistance testing in clinical practice
9. Mutations in retroviral genes associated with drug resistance: 2000-2001 Update
10. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
11. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
12. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
13. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
14. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
15. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
16. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
17. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
18. Usefulness of ritonavir and saquinavir combination therapy in HIV advanced patients failing on indinavir
19. Randomized trial of abacavir (ABC) and nelfinavir (NFV) in combination with efavirenz (EFV) and adefovir dipivoxil (ADV) as salvage therapy in patients with virologic failure receiving indinavir
20. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: A randomized trial (NARVAL, ANRS 088)
21. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients
22. Biologically relevant cut-off values for phenotypic HIV-1 drug susceptibility testing based on the variation in drug susceptibility in untreated individuals
23. Determination of a clinically relevant phenotypic resistance 'cutoff' for abacavir using the Phenosense assay
24. Continuing drug pressure did not alter HIV drug resistance profiles between screening and baseline visits in the prospective trial VIRA3001